184 related articles for article (PubMed ID: 18752592)
1. Rituximab in the treatment of autoimmune haematological disorders.
Provan D; Newland AC; Amadori S; Stasi R
Br J Haematol; 2008 Oct; 143(2):294; author reply 295. PubMed ID: 18752592
[No Abstract] [Full Text] [Related]
2. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for autoimmune haematological diseases.
Barcellini W; Zanella A
Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
[TBL] [Abstract][Full Text] [Related]
4. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
[No Abstract] [Full Text] [Related]
6. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab.
Schumann T; Schmidt E; Booken N; Goerdt S; Goebeler M
Acta Derm Venereol; 2009; 89(1):101-2. PubMed ID: 19197558
[No Abstract] [Full Text] [Related]
7. Treatment with rituximab in benign and malignant hematologic disorders in children.
Giulino LB; Bussel JB; Neufeld EJ;
J Pediatr; 2007 Apr; 150(4):338-44, 344.e1. PubMed ID: 17382107
[No Abstract] [Full Text] [Related]
8. B cell depletion: on the rise.
Hinze CH; Grom AA
J Pediatr; 2007 Apr; 150(4):335-7. PubMed ID: 17382106
[No Abstract] [Full Text] [Related]
9. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.
Kim JJ; Thrasher AJ; Jones AM; Davies EG; Cale CM
Br J Haematol; 2007 Jul; 138(1):94-6. PubMed ID: 17498197
[TBL] [Abstract][Full Text] [Related]
10. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab.
Hennig C; Baumann U; Ilginus C; Horneff G; Foell J; Hansen G
Br J Haematol; 2010 Feb; 148(3):445-8. PubMed ID: 19922533
[TBL] [Abstract][Full Text] [Related]
12. [Biological drugs in the treatment of immunoinflammatory diseases].
Nielsen OH; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2103. PubMed ID: 18565288
[No Abstract] [Full Text] [Related]
13. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
Kittaka K; Dobashi H; Baba N; Iseki K; Kameda T; Susaki K; Kitanaka A; Kubota Y; Ishida T
Scand J Rheumatol; 2008; 37(5):390-3. PubMed ID: 18609263
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
[TBL] [Abstract][Full Text] [Related]
15. [New biological drugs for the treatment of chronic inflammatory diseases].
Skov L; Hegedüs L; Madsbad S; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2162. PubMed ID: 18572482
[No Abstract] [Full Text] [Related]
16. Rituximab for treatment of ocular inflammatory disease: a series of four cases.
Kurz PA; Suhler EB; Choi D; Rosenbaum JT
Br J Ophthalmol; 2009 Apr; 93(4):546-8. PubMed ID: 19321476
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.
Sharma R; Koller L; Barclay P; Liddle C
Intern Med J; 2007 Aug; 37(8):569-71. PubMed ID: 17640190
[TBL] [Abstract][Full Text] [Related]
19. [Biological response modifiers in the treatment of immunoinflammatory diseases].
Skov L; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune pancreatitis in the setting of Castleman disease.
Maithel SK; Pratt W; Kelleher T; Avigan D; Goldman H; Pfeifer W; Pihan GA; Vollmer CM
Pancreas; 2007 Nov; 35(4):384-7. PubMed ID: 18090252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
